Pharsight

Drugs that contain Venetoclax

1. Venclexta patents expiration

VENCLEXTA's oppositions filed in EPO
VENCLEXTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546399 ABBVIE Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(7 years from now)

US10730873 ABBVIE Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(7 years from now)

US8722657 ABBVIE Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
May, 2030

(6 years from now)

US11369599 ABBVIE Melt-extruded solid dispersions containing an apoptosis-inducing agent
May, 2032

(8 years from now)

US11110087 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US9539251 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US11413282 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US11590128 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US10993942 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-185) Jun 08, 2025
Orphan Drug Exclusivity(ODE-211) Nov 21, 2025
Orphan Drug Exclusivity(ODE-239) May 15, 2026
New Chemical Entity Exclusivity(NCE) Apr 11, 2021
Orphan Drug Exclusivity(ODE) Apr 11, 2023
New Indication(I-789) Nov 21, 2021
New Indication(I-795) May 15, 2022
M(M-265) Oct 16, 2023
Orphan Drug Exclusivity(ODE-114) Apr 11, 2023
M(M-228) Jun 08, 2021
New Indication(I-782) Jun 08, 2021

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Treatment: Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that p...

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents